Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)
Funding Amount
Not stated
Deadline
Forecast — expected February 10, 2027
Forecast by the agency; not yet open
Number of Awards
1
Grant Type
Federal
Deadline history & next window
- Cycle
- Not stated
- Next expected
- February 10, 2027
- Tracked since
- September 2026
Forecast: expected to post December 1, 2026; applications expected due February 10, 2027.
Source: Grants.gov forecast for this opportunity.
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Small businesses
- Tribal organizations
- Public & Indian housing authorities
- Nonprofits (501(c)(3))
- For-profit businesses
- City & township governments
- Nonprofits without 501(c)(3) status
- Public colleges & universities
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone.
Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine.
The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses. The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.
Full eligibility text
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Health
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed). Now let's win it.